1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 27, 2025 08:22 ET (12:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.